MX2009006319A - Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. - Google Patents
Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch.Info
- Publication number
- MX2009006319A MX2009006319A MX2009006319A MX2009006319A MX2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A MX 2009006319 A MX2009006319 A MX 2009006319A
- Authority
- MX
- Mexico
- Prior art keywords
- haloalkyl
- alkyl
- phenyl
- group
- halo
- Prior art date
Links
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 title 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- -1 -C1-C3 alkoxy Chemical group 0.000 abstract 4
- 125000001475 halogen functional group Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 2
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 101800002739 Melanin-concentrating hormone Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003667 hormone antagonist Substances 0.000 abstract 1
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 abstract 1
- 102000047659 melanin-concentrating hormone Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención se refiere a un compuesto antagonista de hormona de concentración de melanina de la fórmula I, en donde '-----' está ausente o es opcionalmente un enlace; q es 1 ó 2; R1 independientemente se selecciona de hidrógeno, alquilo de C1-C2, halógeno, hidroxi, haloalquilo de C1-C2, ciano, -O-C3-C4 cicloalquilo, y -OC1-C2 haloalquilo; R2 se selecciona del grupo que consiste de hidrógeno, alquilo de C1-C3, hidroxi, alcoxi de C1-C3, ciano, haloalquilo de C1-C2, -OC1-C2 haloalquilo, y halógeno; R3 se selecciona del grupo que consiste de hidrógeno, alquilo de C1-C4, haloalquilo de C2-C4, alquilo de C2-C4-OH, cicloalquilo de C3-C6, -CH2C3-C6-cicloalquilo, alquilo de C2-C4-O-alquilo de C1-C4, -C(O)-alquilo de C1-C4, -CH2-tiazol, fenilo, bencilo, tetrahidrotiopiranilo, y tetrahidropiranilo, en donde el grupo cicloalquilo, tetrahidrotiopiranilo, tetrahidropiranilo y tiazolilo está opcionalmente substituido con uno o dos grupos independientemente seleccionados de del grupo que consiste de halógeno, hidroxi, alquilo de C1-C2 y haloalquilo de C1-C2; o una sal farmacéuticamente aceptable, enantiómero, diaestereómero, o mezcla de los mismos, útiles en el tratamiento, prevención o mejora de síntomas asociados con obesidad y enfermedades relacionadas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87001106P | 2006-12-14 | 2006-12-14 | |
| PCT/US2007/084812 WO2008076562A1 (en) | 2006-12-14 | 2007-11-15 | 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009006319A true MX2009006319A (es) | 2009-12-14 |
Family
ID=39204735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009006319A MX2009006319A (es) | 2006-12-14 | 2007-11-15 | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8049013B2 (es) |
| EP (1) | EP2089397B1 (es) |
| JP (1) | JP5269804B2 (es) |
| KR (1) | KR20090082484A (es) |
| CN (1) | CN101558075A (es) |
| AR (1) | AR064127A1 (es) |
| AU (1) | AU2007334171A1 (es) |
| BR (1) | BRPI0721086A2 (es) |
| CA (1) | CA2671765A1 (es) |
| CL (1) | CL2007003480A1 (es) |
| EA (1) | EA015559B1 (es) |
| ES (1) | ES2392276T3 (es) |
| MX (1) | MX2009006319A (es) |
| PE (1) | PE20081572A1 (es) |
| TW (1) | TW200831082A (es) |
| WO (1) | WO2008076562A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5627574B2 (ja) | 2008-06-03 | 2014-11-19 | インターミューン， インコーポレイテッド | 炎症性および線維性疾患を治療するための化合物および方法 |
| SA110310332B1 (ar) | 2009-05-01 | 2013-12-10 | Astrazeneca Ab | مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل ) |
| NZ600603A (en) | 2009-12-18 | 2013-07-26 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
| NZ600605A (en) | 2009-12-18 | 2013-08-30 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mglur5 receptors |
| ES2527466T3 (es) | 2010-07-06 | 2015-01-26 | Astrazeneca Ab | Agentes terapéuticos 976 |
| UY34194A (es) | 2011-07-15 | 2013-02-28 | Astrazeneca Ab | ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad? |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN107400044B (zh) * | 2013-01-25 | 2020-08-07 | 中央硝子株式会社 | α,α-二氟乙醛的制造方法 |
| MX382781B (es) | 2014-04-02 | 2025-03-13 | Intermune Inc | Piridinonas anti-fibroticas. |
| CN107698498A (zh) * | 2016-08-08 | 2018-02-16 | 罗楹 | 一种羟尼酮的制备方法 |
| CN107698499A (zh) * | 2016-08-08 | 2018-02-16 | 罗楹 | 一种羟尼酮的制备方法 |
| CN108997138A (zh) * | 2018-08-17 | 2018-12-14 | 济南和润化工科技有限公司 | 一种无溶剂催化氢化法生产对氟苯胺的方法 |
| EP4429663A4 (en) * | 2021-11-09 | 2025-09-17 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS USED AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELL AGONISTS 2 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0124627D0 (en) | 2001-10-15 | 2001-12-05 | Smithkline Beecham Plc | Novel compounds |
| ATE446962T1 (de) * | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
-
2007
- 2007-11-15 ES ES07864454T patent/ES2392276T3/es active Active
- 2007-11-15 AU AU2007334171A patent/AU2007334171A1/en not_active Abandoned
- 2007-11-15 BR BRPI0721086-8A patent/BRPI0721086A2/pt not_active IP Right Cessation
- 2007-11-15 MX MX2009006319A patent/MX2009006319A/es active IP Right Grant
- 2007-11-15 WO PCT/US2007/084812 patent/WO2008076562A1/en not_active Ceased
- 2007-11-15 US US12/515,432 patent/US8049013B2/en not_active Expired - Fee Related
- 2007-11-15 CA CA002671765A patent/CA2671765A1/en not_active Abandoned
- 2007-11-15 EA EA200970582A patent/EA015559B1/ru not_active IP Right Cessation
- 2007-11-15 CN CNA200780046086XA patent/CN101558075A/zh active Pending
- 2007-11-15 JP JP2009541454A patent/JP5269804B2/ja not_active Expired - Fee Related
- 2007-11-15 EP EP07864454A patent/EP2089397B1/en not_active Not-in-force
- 2007-11-15 KR KR1020097012244A patent/KR20090082484A/ko not_active Abandoned
- 2007-11-28 TW TW096145231A patent/TW200831082A/zh unknown
- 2007-12-04 AR ARP070105416A patent/AR064127A1/es unknown
- 2007-12-04 PE PE2007001715A patent/PE20081572A1/es not_active Application Discontinuation
- 2007-12-04 CL CL200703480A patent/CL2007003480A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101558075A (zh) | 2009-10-14 |
| AU2007334171A1 (en) | 2008-06-26 |
| KR20090082484A (ko) | 2009-07-30 |
| EP2089397A1 (en) | 2009-08-19 |
| CL2007003480A1 (es) | 2008-07-11 |
| EP2089397B1 (en) | 2012-08-29 |
| JP2010513292A (ja) | 2010-04-30 |
| TW200831082A (en) | 2008-08-01 |
| JP5269804B2 (ja) | 2013-08-21 |
| ES2392276T3 (es) | 2012-12-07 |
| EA200970582A1 (ru) | 2010-02-26 |
| CA2671765A1 (en) | 2008-06-26 |
| EA015559B1 (ru) | 2011-08-30 |
| PE20081572A1 (es) | 2008-12-27 |
| WO2008076562A1 (en) | 2008-06-26 |
| BRPI0721086A2 (pt) | 2014-02-25 |
| AR064127A1 (es) | 2009-03-11 |
| US8049013B2 (en) | 2011-11-01 |
| US20100069352A1 (en) | 2010-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009006319A (es) | Derivados de 5-[4-(azetidin-3-iloxi)-fenil] -2-fenil-5h tiazolo [5,4-c] piridin-4-ona y su uso como antagonistas del receptor de mch. | |
| MX2009004900A (es) | Arilamidas sustituidas por tiazol u oxazol. | |
| WO2005080384A3 (en) | Benzimidazole derivative and use as aii receptor antagonist | |
| EP2592070A3 (en) | Tetrazole-substituted arylamides | |
| MXPA05011670A (es) | Derivados de azetidincarboxamida y su uso en el tratamiento de trastornos mediados por el receptor cb1. | |
| MY150507A (en) | Polycyclic compound | |
| WO2005103039A8 (en) | 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists | |
| TW200732313A (en) | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
| TNSN07014A1 (en) | New heterocyclic carboxylic acid amide derivatives | |
| MX2009010731A (es) | Derivados de acido 1-(1-bencilpiperidin-4-il)benzimidazol-5-carbox ilico para el tratamiento de diabetes mellitus. | |
| PL1828177T3 (pl) | Nowi antagoniści receptora MCH | |
| KR20090024811A (ko) | 히스타민 ｈ3 수용체 조절제로서의 사이클로프로필 아민 유도체 | |
| IL195747A0 (en) | Pyrimidine and quinazoline derivatives as modulators of somatostatine receptor activity | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| WO2007125398A3 (en) | : sulfonamide compounds as antagonists of the n-type calcium channel | |
| TW200531694A (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
| TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
| MX2010012421A (es) | 5-[5-[2-(3,5-bis(trifluormetil)fenil)-2-metilpropanoilmetilamino] -4-(4-fluoro-2-metilfenil)]-2-piridinil-2-alquil-prolinamida como antagosnistas del receptor de neurocinina 1. | |
| TW200504021A (en) | Substituted anilide ligands for the thyroid receptor | |
| CY1110950T1 (el) | Ενωσεις ιμιδαζολιδινονυλ αμινοπυριμιδινης για τη θεραπευτικη αντιμετωπιση του καρκινου | |
| PL2139866T3 (pl) | Krystaliczny 1-((2’-cyjanobifenylo-4-ylo)metylo)-2-etoksy-1H-benzo[d]imidazolo-7-karboksylan 1-(cykloheksyloksykarbonyloksy)etylu i sposób jego wytwarzania | |
| WO2004080411A3 (en) | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto | |
| MX2010007350A (es) | Derivados de 2-heteroaroil-imidazol[1,2-a]piridina, su preparacion y aplicacion terapeutica. | |
| EA015500B9 (ru) | Новые антагонисты мсн рецепторов | |
| PE20130781A1 (es) | Agentes terapeuticos 976 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |